Gateways to Clinical Trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 25, Issue 9, 2003, Pages 747-771

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 5 AZA 2' DEOXYCYTIDINE; 6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; 7 HYDROXYSTAUROSPORINE; ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMGN 0007; ANECORTAVE; AOD 9604; CANFOSFAMIDE; CERIVASTATIN; CP 461; CS 003; CS 461; DOXORUBICIN; FENOFIBRATE; FUROSEMIDE; GADOLINIUM TEXAPHYRIN; GLUTAMINE; GPI 15715; HYB 165; INDISULAM; ISOPHANE INSULIN; L 796568; LUTETIUM TEXAPHYRIN; MATUZUMAB; ONO 61626; PAMIDRONIC ACID; PARATHYROID HORMONE; PEXELIZUMAB; PIVALOYLOXYMETHYL BUTYRATE; PREGABALIN; PRO 2000; RAGAGLITAZAR; RG 228; RPI 4610; RUBITECAN; S ADENOSYLMETHIONINE; SOLIFENACIN; SRL 172; T 138067; TECADENOSON; TEMSIROLIMUS; TEZOSENTAN; TIPIFARNIB; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; XIMELAGATRAN;

BLEEDING; CANCER; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG INDICATION; DRUG RESEARCH; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; LIVER FAILURE; MEDICAL LITERATURE; MUSCULOSKELETAL DISEASE; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; TREATMENT OUTCOME; VEIN THROMBOSIS;

CLINICAL TRIALS; HUMANS;

EID: 0346502201     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (159)

1. Saunthararajah, Y., Hillery, C.A., Lavelle, D. et al. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003: Advance publication.
2. Giardina, P., Olivieri, N.F., Nisbet-Brown, N.F. et al. ICL670, a tridentate orally-active iron chelator, provides sufficient net negative iron balance and increased serum iron binding capacity in iron-overloaded patients with thalassemia. 7th Congr Eur Hematol Assoc (June 6, 2002, Florence) 2002: Abst 0236.
3. Kereiakes, D.J., Szyniszewski, A.M., Wahr, D. et al. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment. Procedural and long-term results. Circulation 2003, 108(11): 1310.
4. Serebruany, V.L., Malinin, A.I., O'Connor, C.M., Gurbel, P.A. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). Am Heart J 2003, 146(1): 91.
5. Steinmetz, N., Taillefer, R., Hendel, R.C. et al. Simultaneous dual isotope 201T1/99mTc-annexin (Apomate(TM)) SPECT in detection of acute myocardial infarction: Initial results of a phase II multicenter trial. J Nucl Med 2002, 43 (5, Suppl.): Abst No. 11.
6. Topol, E.J., Easton, D., Harrington, R.A. et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003, 108(4): 399.
7. Russell, S.D., Adams, K.F. Jr., Shaw, J.P., Gattis, W.A., O'Connor, C.M. Results of a twelve week double-blind, placebo-controlled, multicenter study of oral conivaptan to assess functional capacity in patients with class III chronic heart failure. J Cardiac Fail 2003, 9 (5, Suppl.): Abst 215.
8. Torre-Amione, G., Kaluski, E., Stangl, K. et al. Low dose tezosentan, an intravenous dual endothelin receptor antagonist, decreases type B-natriuretic peptide levels in patients with acute decompensated heart failure. J Cardiac Fail 2003, 9 (5, Suppl.): Abst 351.
9. Burnett, J.C., Smith, W.B., Ouyang, J., Zimmer, C.A., Orlandi, C. Tolvaptan (OPC-41061), a V2 vasopressin receptor antagonist, protects against the decline in renal function observed with loop diuretic therapy. J Cardiac Fail 2003, 9 (5, Suppl.): Abst 036.
10. Granger, C.B., Mahaffey, K.W., Weaver, W.D. et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction. The COMPlement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003, 108(10): 1184.
11. Mahaffey, K.W., Granger, C.B., Nicolau, J.C. et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction. The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003, 108(10): 1176.
12. Wallentin, L., Wilcox, R.G., Weaver, W.D. et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: The ESTEEM randomised controlled trial. Lancet 2003, 362(9386): 789.
13. Prystowsky, E.N., Niazi, I., Curtis, A.B. et al. Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel AI-adenosine receptor agonist. J Am Coll Cardiol 2003, 42(6): 1098.
14. Sorensen, A.G. Results of MS-325-13: A phase III magnetic resonance angiography trial with MS-325, a blood pool contrast agent, for the detection of aortoiliac occlusive disease. Am J Cardiol 2003, 92 (6A, Suppl.): Abst TCT-179.
15. Deitcher, S.R., Fraschini, G., Himmelfarb, J., Schuman, E., Mouginis, T.L. Dose-ranging trial utilizing a recombinant urokinase (urokinase alfa; ABT-120) in the treatment of occluded central venous catheters primarily in oncology subjects. Blood 2002, 100 (11, Part 1): Abst 2763.
16. Muls, E. et al. Recombinant leptin s.c. normalises energy homeostasis in congenital lipodistrophy. Int J Obes 2003, 27 (Suppl. 1): Abst T1:02-3.
17. Lindh, V., Wiklund, U., Blomquist, H.K., Hakansson, S. EMLA cream and oral glucose for immunization pain in 3-month-old infants. Pain 2003, 104(1-2): 381.
18. Soubrane, G., Dahlin, D., Robertson, S. Posterior juxtascleral administration of anecortave acetate for exudative AMD-A unique-route of administration. 14th Congr Eur Soc Ophthalmol (June 7, 2003, Madrid) 2003: Abst FP026.
19. Murray, J., Wilson, S., Klein, S., Yellin, A., Loh, E. The clinical response to tigecycline in the treatment of complicated intraabdominal injections in hospitalized patients, a phase 2 clinical trial. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14, 2003, Chicago) 2003: Abst L-739.
20. Neri, S. et al. Role of ademetionine (S-adenosylmethionine) in cyclosporin-induced cholestasis. Clin Drug Invest 2002, 22(3): 191.
21. Kuipers, M., Smulders, R., Krauwinkel, W. The safety, tolerability, and pharmacokinetics of solifenacin succinate in patients with hepatic impairment. 33rd Annu Meet Int Continence Soc (Oct 5, 2003, Florence) 2003: Abst 308.
22. Abul Futuh, A.R. Biochemical response in Viscum fraxini-2 (VF-2) therapy decreases the development of hepatocellular carcinoma improves the survival of chronic hepatitis C patients. Gut 2002, 51 (Suppl. 3): Abst WED-G-328.
23. Krause, D., Birmingham, W., Schranz, J. Safety results from a phase 3, randomized, double-blind, double-dummy study of anidulafungin (ANID) vs. fluconazole (FLU) in patients (pts) with esophageal candidiasis (EC). 41st Annu Meet Infect Dis Soc Am (Oct 9, 2003, San Diego) 2003: Abst 136.
24. Tabet, S.R., Callahan, M.M., Mauck, C.K. et al. Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J Acquir Immune Defic Syndr (JAIDS) 2003, 33(4): 476.
25. Clement, S., Still, J.G., Kosutic, G., McAllister, R.G. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: The glucose stabilization effects of HIM2. Diabetes Technol Ther 2002, 4(4): 459.
26. Levetan, C., Want, L.L., Weyer, C. et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 2003, 26(1): 1.
27. Skyler, J.S. Efficacy and safety of inhaled insulin (Exubera®) compared to subcutaneous insulin therapy in an intensive insulin regimen in patients with type 1 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes 2002, 51 (Suppl. 2): Abst 540-P.
28. Feng, J., Lin, D., Zheng, A., Cheng, N. Chromium picolinate reduces insulin requirement in people with type 2 diabetes mellitus. Diabetes 2002, 51 (Suppl. 2): Abst 1929-PO.
29. Kipnes, M., Dandona, P., Tripathy, D., Still, J.G., Kosutic, G. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 2003, 26(2): 421.
30. Hollander, P.A., Levy, P., Fineman, M.S. et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2003, 26(3): 784.
31. Strand, J., Sandeman, D., Skovsted, B., Edsberg, B., Müller, P. Ragaglitazar (NNC 61-0029, (-)DRF 2725): The efficacy and safety or a novel dual PPARalpha and PPARgamma agonist in patients with type 2 diabetes. Diabetes 2002, 51 (Suppl. 2): Abst 583-P.
32. Samuelsson, S., Bergh, S., Ohman, P., Ericsson, H. Systemic exposure of tesaglitazar (Galida™) is not affected by intake of food, 18th Int Diabetes Fed Congr (Aug 24, 2003, Paris) 2003: Abst 2300.
33. Samuelsson, S., Bergh, S., Ohman, P., Ericsson, H. Food does not affect the pharmacokinetics of tesaglitazar (Galida™). Diabetes 2003, 52 (Suppl, 1): Abst 567-P.
34. Glicklich, A., Bays, H., Russell, T., Weinstein, S., Hollander, P. Axokine® promotes weight loss in overweight obese patients with type 2 diabetes mellitus. Obes Res 2003, 11 (Suppl.): Abst 471-P.
35. Glicklich, A., Russell, T., Weissman, P., Weinstein, S., Smith, D. Axokine induces weight loss in 12 week study of overweight and obese subjects with type 2 diabetes regarless of therapeutic class of oral anti-diabetes medications used. Obes Res 2003, 11 (Suppl.): Abst 100-OR.
36. Cappellini, M.D., Galanello, R., Piga, A. et al. Update on the effects of ICL670, a novel tridentate oral iron chelator, on liver iron concentration in patients with transfusion dependent iron overload. 7th Congr Eur Hematol Assoc (June 6, 2002, Florence) 2002: Abst 0610.
37. Sebestjen, M. et al. Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia. J Intern Med 2002, 251(1): 77.
38. Rowbotham, M., Young, J.P. Jr., Sharma, U., Knapp, K. Pregabalin shows reduction in pain by day three of treatment. 7th Congr Eur Fed Neurol Soc (Aug 30, 2003, Helsinki) 2003: Abst 465.
39. Herd, C., Vos, E., Belyea, C., Wittert, G. Safety and tolerability of anti-obesity compound AOD9604 in obese men - Results from a phase IIA, double-blind, placebo controlled study. Obes Res 2003, 11 (Suppl.): Abst 444-P.
40. Larsen, T.M. et al. Effect of a 28-d treatment with L-796568, a novel beta3-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr 2002, 76(4): 780.
41. Fogteloo, A.J., Pijl, H., Frolich, M., McCamish, M., Meinders, A.E. Effects of recombinant human leptin treatment as an adjunct of moderate energy restriction on body weight, resting energy expenditure and energy intake in obese humans. Diabetes Nutr Metab 2003, 16(2): 109-14.
42. Black, D.M., Ensrud, K., Greenspan, S. et al. The effects of PTH, alendronate alone or in combination on bone mass and turnover: 12 Month results of the PaTH trial. 25th Annu Meet Am Soc Bone Miner Res (ASBMR) (Sept 19, 2003, Minneapolis) 2003: Abst 1007.
43. Bauer, D.C., Garnero, P., Bilezikian, J.P. et al. Effect of PTH, alendronate, or PTH plus alendronate oh biochemical markers of bone turnover: One year results of the PaTH study. 25th Annu Meet Am Soc Bone Miner Res (ASBMR) (Sept 19, 2003, Minneapolis) 2003: Abst 1115.
44. Black. D.M., Greenspan, S.L., Ensrud. K.E. et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 2003, 349(13): 1207.
45. Schwartz, G., Dutcher, J.P., Vogelzang, N.J. et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 91.
46. Gandara, D.R., Lara, P.N., Longmate, J. et al. The cyclin-dependent kinase (CDK) Inhibitor UCN-01 plus cisplatin in advanced solid tumors: A California Cancer Consortium Phase I Trial. Proc Am Soc Clin Oncol 2003, 22: Abst 987.
47. Thomas, J.P., Ramanathan, R.K., Wilding, G. et al. A phase I study of motexafin gadolinium (MGd) in combination with doxorubicin (Dox). Proc Am Soc Clin Oncol 2003, 22: Abst 909.
48. Hammond, L., Abbruzzese, J., Beeram, M. et al. Phase I and pharmacokinetic (PK) trial of 3′-C-ethylnylcytidine (TAS-106) in solid tumors. Eur J Cancer 2002, 38 (Suppl. 7): Abst 364.
49. Tabernero, J., Rojo, F., Jiménez, E. et al. A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR. Eur J Cancer 2002, 38 (Suppl. 7): Abst 216.
50. Anzai, Y., Piccoli, C.W., Outwater, E.K. et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: Phase III safety and efficacy study. Radiology 2003, 228(3): 777.
51. Ward, E. Oral glutamine in paediatric oncology patients: A dose finding study. Med Pediatr Oncol 2003, 41(4): Abst S024.
52. Goel, S., Desai, K., Bulgaru, A. et al. A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type 1 regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. Clin Cancer Res 2003, 9(11): 4069.
53. Terret, C., Zanetta, S., Roche, H. et al. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). Eur J Cancer 2003, 39(8): 1097.
54. Gadgeel, S.M., Boinpally, R.R., Heilbrun, L.K. et al. A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design. Invest New Drugs 2003, 21(1): 63.
55. Punt, C.J.A., Boni, J., Bruntsch, U., Peters, M., Thielert, C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 2003, 14(6): 931.
56. Morris, D.G., Forsyth, P.A., Paterson, A.H. et al. A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies. Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 92.
57. Goetz, A.D., Rowinsky, E.K., Tolcher, A. et al. Phase I and pharmacokinetic (PK) study of escalating doses of rubitecan in combination with weekly gemcitabine in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2003, 22: Abst 626.
58. Adjei, A.A., Croghan, G.A., Erlichman, C. et al. A phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 2003, 9(7): 2520.
59. Edelman, M.J., Bauer, K., Khanwani, S. et al. Clinical and pharmacologic study of tributyrin: An oral butyrate prodrug. Cancer Chemother Pharmacol 2003, 51(5): 439.
60. Bennouna, J., Fumoleau, P., Armand, J.P. et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 2003, 14(4): 630.
61. Laverdiere, C., Kolb, E.A., Supko, J.G. et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003, 98(4): 832.
62. Burstein, H.J., Parker, L.M., Savoie, J. et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat 2002, 76 (Suppl. 1): Abst 446.
63. Dittrich, C., Petruzelka, L., Vodvarka, P. et al. Phase I study of pemetrexed (Alimta) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2002, 76 (Suppl. 1): Abst 529.
64. Lipton, A., Body, J.-J., Greipp, P. et al. AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast cancer-related bone metastases. Cancer Invest 2003, 21 (Suppl. 1): Abst 73.
65. Miller, K.D., Murry, D.J., Curry, E. et al. A phase I study of 2-methoxyestradiol (2ME2) plus docetaxel (D) in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 442.
66. Sledge, G.W., Miller, K.D., Haney, L.G. et al. A phase I study of 2-methoxyestradiol (2ME2) in patients (pts) with refractory metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 441.
67. Hortobagyi, G., Weng, D., Elias, A. et al. Angiozyme treatment of stage IV metastatic breast cancer patients: Assessment of serum markers of angiogenesis. Breast Cancer Res Treat 2002, 76 (Suppl. I): Abst 362.
68. Nabid, A., Ganguly, P., Venkatesan, V. et al. A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy. Int J Radiat Oncol Biol Phys 2002, 54 (2, Suppl.): Abst 2134.
69. Crombet, T., Osorio, M., Cruz, T. et al. Use of the anti-EGFR antibody h-R3 in combination with radiotherapy in the treatment of advanced head and neck cancer. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 53.
70. Mainwaring, P.N., Van Cutsem, E., Van Laethem, J.-L. et al. A multicentre randomised phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil-based chemotherapy. Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 611.
71. Sharma, S., Kemeny, N., Kelsen, D.P. et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol 2002, 13(7): 1067.
72. Burke, T.W., Walker, C.L. Arzoxifene as therapy for endometrial cancer. Gynecol Oncol 2003, 90 (2, Suppl, 1): S40.
73. Stadler, W.M., Rosner, G., Rini, B. et al. Successful implementation of the randomized discontinuation trial design (RDTD) with the putative antiangiogenic agent carboxyaminoimidazole (CAI) in renal cell carcinoma (RCC). A Cancer and Leukemia Group B (CALGB) Study. Proc Am Soc Clin Oncol 2003, 22: Abst 773.
74. Yang, J.C., Haworth, L., Sherry, R.M. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New Engl J Med 2003, 349(5): 427.
75. Thompson, J.A., Figlin, R.A., Sifri-Steele, C., Berenson, R.J., Frohlich, M.W. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res 2003, 9(10): 3562.
76. Amato, R.J., Pérez, C., Pagliaro, L. Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer. Invest New Drugs 2002, 20(4): 413.
77. Leung, T.W., Feun, L., Posey, J., Stagg, R.J., Levy, M.D., Venook, A.P. A phase II study of T138067-sodium in patients (pts) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 572.
78. Marrero, J.A., Hussain, H.K., Fontana, R.J. et al. Antiangiogenesis therapy for hepatocellular carcinoma with tetrathiomolybdate: Report of a pilot trial. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 908.
79. Keer, H.N., Reid. T., Sreedharan, S. Pivanex activity in refractory non-small cell lung cancer, a phase II study. Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 1253.
80. Braybrooke, J.P., Ranson, M., Manegold, C. et al. Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Lung Cancer (Ireland) 2003, 41(2): 215.
81. Jahan, T.M., Sandler, A., Burris, H. et al. A phase II study of T138067-sodium in prior taxane-treated patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 1282.
82. Garaventa, A., Luksch, R., Lo Piccolo, M.S. et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003, 9(6): 2032.
83. Sabbatini, P., Brown, J., Peters, W.A. et al. Phase I/II study of CT-2103 (Xyotax) in patients with recurrent ovarian cancer. Cancer Invest 2003, 21 (Suppl. 1): Abst 28.
84. Kavanagh, J.J., Kudelka, A.P., Lewis, L. et al. TLK286: Phase 2 study in patients with platinum resistant ovarian cancer. Cancer Invest 2003, 21 (Suppl. 1): Abst 69.
85. Colombo, N., Sessa, C., Perotti, A. et al. Phase II study of 3-hour infusion ET 743 in patients with refractory/relapsing ovarian cancer. Cancer Invest 2003, 21 (Suppl. 1): Abst 27.
86. Lapointe, R., Letourneau, R., Steward, W. et al. Phase 2 study of troxacitabine in chemotherapy naive patients with advanced cancer of the pancreas. Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 565.
87. Muggia, F.M., Liebes, L., Hazarika, M. et al. Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days. Anti-Cancer Drugs 2002, 13(8): 819.
88. Wilding, G., Sweeney, C., King, D.M. et al. Phase 2, multicenter, randomized, double blind, safety, pharmacokinetic, pharmocodynamic and efficacy study of two doses of 2methoxyestradiol admninistred orally in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 338.
89. Petrylak, D.P. A phase II study of CP-461 in prostate cancer patients with measurable disease. Cancer Invest 2003, 21 (Suppl. 1): Abst 51.
90. Beer, T.M., Garzotto, M., Eilers, K.M., Lemmon, D. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. J Urol 2003, 169(5): 1738.
91. Patel, S.R., Beach, J., Papadopoulos, N. et al. Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer 2003, 97(11): 2848.
92. Ajani, J.A., Baker, J., Faust, J. et al. Developing strategies for second-line therapy of advanced gastric carcinoma: Preliminary results with RFS-2000 (Rubitecan™). Cancer Invest 2003, 21 (Suppl. 1): Abst 18.
93. Kantarjian, H.M. Clofarabine-A new nucleoside analogue with significant activity in leukemia. Cancer Invest 2003, 21 (Suppl. 1): Abst 3.
94. De Angelo, D.J., Yu, D., Dodge, R.K. et al. A phase II study of 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute myeloblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): CALGB study 19801. Blood 2002, 100 (11, Part 1): Abst 743.
95. Smith, B.D., Levis, M., Brown, P. et al. Single agent CEP-701, a novel FLT-3 inhibitor, shows initial response in patients with refractory acute myeloid leukemia. Blood 2002, 100 (11, Part 1): Abst 314.
96. Ravoet, C., Mineur, P., Robin, V. et al. Phase I-II study of a farnesyl transferase inhibitor (FTI). SCH66336, in patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML). Blood 2002, 100 (11, Part 1): Abst 3136.
97. Hegde, U., White, T., Stetler-Stevenson, M. et al. Phase I study of combination rituximab (CD20) and apolizumab (HuID10) monoclonal antibody therapy in previously treated B-cell lymphoma and chronic lymphocytic leukemia. Blood 2002, 100 (11, Part 1): Abst 1389.
98. Kantarjian, H.M., O'Brien, S., Cortes, J. et al. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003, 98(3): 522.
99. Cortes, J.E., Daley, G., Talpaz, M. et al. Pilot study of SCH66336 (lonafarnib), a farnesyl transferase inhibitor (FTI), in patients with chronic myeloid leukemia (CML) in chronic or accelerated phase resistant or refractory to imatinib. Blood 2002, 100 (11, Part 1): Abst 614.
100. List, A.F., DeAngelo, D., O'Brien, S.O. et al. Phase I study of continuous oral administration of lonafarnib (Sarasar™) in patients with advanced hematologic malignancies. Blood 2002, 100 (11, Part 1): Abst 3120.
101. List, A., Cortes, J., DeAngelo, D. et al. Phase I study of continuous oral administration of lonafarnib (SCH66336) in patients with advanced myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia blast crisis (CMLBC), and acute lymphoblastic leukemia (ALL). Cancer Invest 2003, 21 (Suppl. 1): Abst 67.
102. Nicholson, S., Guile, K., John, J. et al. A randomized phase II trial of SRL172 (Mycobacterium vaccae) ± low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res 2003, 13(4): 389.
103. Hunt, B.J., Parmar, K., Jones, R.W., Schey, S.A. Markers of endothelial and haemostatic activation in the use of CC-4047, a structural analogue of thalidomide, in relapsed myeloma. Blood 2002, 100 (11, Part 1): Abst 3216.
104. Demierre, M.F. et al. Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides. Arch Dermatol 2003, 139(5): 624.
105. Chez, M.G., Buchanan, C.P., Komen, J. L-Carnosine therapy for intractable epilepsy in childhood: Effect on EEG. Epilepsia 2002, 43 (Suppl. 7): Abst 1.178.
106. Miller, R., Frame, B., Corrigan, B. et al. Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizures. 7th Congr Eur Fed Neurol Soc (Aug 30, 2003, Helsinki) 2003: Abst 552.
107. French, J.A., Kugler, A.R., Robbins, J.L., Knapp, L.E., Garofalo, E.A. Dose-response trial of pregabalin adjunctive therapy in patients with patrial seizures. Neurology 2003, 60(10): 1631.
108. Rozen, T. Melatonin as treatment for indomethacin-responsive headache syndromes. Cephalalgia 2003, 23(7): Abst P6Q7.
109. Roth, T., Walsh, J. Phase II study of the selective ML-1 receptor agonist TAK-375 in a first night effect model of transient insomnia. Sleep 2003, 26 (Suppl.): Abst 0739.L.
110. Erman, M., Seiden, D., Zammit, G. Phase II study of the selective ML-1 receptor agonist TAK-375 in subjects with primary chronic insomnia. Sleep 2003, 26 (Suppl.): Abst 0748.L.
111. Miller, D.H., Khan, O.A., Sheremata, W.A. et al. A controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 2003, 348(1): 15.
112. Bowen, J.D., Maravilla, K., Margolin, S.B. Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis. Multiple Scler 2003, 9(3): 280.
113. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The TEMPO Study. Arch Neurol 2002, 59(12): 1937-43.
114. Koga, Y., Akita, Y., Ueki, I., Fukiyama, R., Matsuishi, T. Novel therapeutic trial of L-arginine on acute phase of stroke in MELAS. J Jpn Biochem Soc 2003, 75(8): Abst 4S64-4.
115. Bycroft, J., Leaker, B., Wood, S., Knight, S., Shan, J., Craggs, M. The effect of darifenacin on neurogenic detrusor overactivity in patients with spinal cord injury. 33rd Annu Meet Int Continence Soc (Oct 5, 2003, Florence) 2003: Abst 190.
116. Grijalva, I., Guízar-Sahagún, G., Castañ eda-Hernández, G. et al. Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: A randomized, double-blind, placebo-controlled trial. Pharmacotherapy 2003, 23(7): 823.
117. Montgomery, S.A. Pregabalin in generalized anxiety disorder: Speed of onset. Eur Neuropsychopharmacol 2003, 13 (Suppl. 4): Abst P.3.054.
118. Lydiard, B. Efficacy of pregabalin in treating psychic and somatic symptoms in generalized anxiety disorder (GAD). Eur Neuropsychopharmacol 2003, 13 (Suppl. 4): Abst P.3.055.
119. Feltner, D.E., Crockatt, J.G., Dubovsky, S.J. et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003, 23(3): 240.
120. Dunner, D.L., Goldstein, D.J., Mallinckrodt, C., Lu, Y., Derke, M.J. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 2003, 18(2): 53.
121. Detke, M., Gilaberte, I., Perahia, D. et al. Duloxetine vs placebo in the prevention of relapse of major depressive disorder. Eur Neuropsychopharmacol 2003, 13 (Suppl. 4): Abst P.1.204.
122. Detke, M.J., Lu, Y.L., Goldstein, D.J., McNamara, R.K., Demitrack, M.A. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002, 36(6): 383.
123. Hay, D., Wohlreich, M., Mallinckrodt, C., Watkin, J. Open-label duloxetine treatment of major depression: Comparisons between elderly (age >65) and younger (age <65) patients. 11th Int Congr Int Psychogeriatr Assoc (Aug 17, 2003, Chicago) 2003: Abst PA-043.
124. Montgomery, S.A. Safety of agomelatine in the treatment of depression: Absence of discontinuation symptoms. Eur Neuropsychopharmacol 2003, 13 (Suppl. 4): Abst P.1.084.
125. Lecrubier, Y. A partial D3 receptor agonist in schizophrenia. Eur Neuropsychopharmacol 2003, 13 (Suppl. 4): Abst S.27.02.
126. Boeve, B.F., Silber, M.H., Ferman, T.J. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: Results in 14 patients. Sleep Med 2003, 4(4): 281.
127. Pollack, M. Pregabalin in generalized anxiety disorder: Influence of subsyndromic depression. Eur Neuropsychopharmacol 2003, 13 (Suppl. 4): Abst P.3.056.
128. Cardozo, L., Prescott, K., Serdarevic, D., Skillern, L. Can medication prolong warning time? 33rd Annu Meet Int Continence Soc (Oct 5, 2003, Florence) 2003: Abst 74.
129. Chapple, C., Rechberger, T., Al-Shukri, S., Meffan, P., Everaert, K., Ridder, A. Results of a randomized phase 3 study comparing solifenacin succinate with tolterodine and placebo in patients with overactive bladder. 33rd Annu Meet Int Continence Soc (Oct 5, 2003, Florence) 2003: Abst 121.
130. Smulders, R., Smith, N., Krauwinkel, W., Balan, G. The safety, tolerability, and pharmacokinetics of solifenacin succinate in patients with mild, moderate, and severe renal disease. 33rd Annu Meet Int Continence Soc (Oct 5, 2003, Florence) 2003: Abst 303.
131. Lobo, R.A., Dorin, M.H., Lewis, V., Simon, J.A., Grubb, G.S. Safety and efficacy of conjugated estrogens (CE)/trimegestone (TMG) on vasomotor symptoms, vaginal atrophy, and metabolic profiles in a double-blind, randomized, placebo-controlled study. Fertil Steril 2003, 80 (Suppl. 3): Abst 0-42.
132. Pickar, J.H., Yeh, I.-T., Cunnane, M.F., Archer, D.F. Impact of conjugated estrogens (CE)/trimegestone (TMG) on endometrial hyperplasia and bleeding profiles in a double-blind, randomized, placebo-controlled study. Fertil Steril 2003, 80 (Suppl. 3): Abst O-47.
133. Lindsay, R., Gallagher, J.C., Harrison, D.D., Zinaman, M.J., Pickar, J.H. Effect of conjugated estrogens (CE)/trimegestone (TMG) on bone mineral density (BMD) in early postmenopausal women in a double-blind, randomized, placebo-controlled study. Fertil Steril 2003, 80 (Suppl. 3): Abst O-45.
134. Squadrito, F., Altavilla, D., Crisafulli, A. et al. Effect of genistein on endothelial function in postmenopausal women: A randomized, double-blind, controlled study. Am J Med 2003, 114(6): 470.
135. Schelfhout, V., Louis, R., Lenz, W., Pauwels, R., Joos, G. The triple neurokinin receptor antagonist CS-003 inhibits neurokinin A (NKA)-induced bronchoconstriction in patients with asthma. Eur Respir J 2003, 22 (Suppl. 45): Abst P2664.
136. Gauvreau, G.M., Becker, A.B., Boulet, L.P. et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2003, 112(2): 331.
137. Furuie, H., Nakagawa, S., Kawashima, M., Murakami, M., Irie, S. Suppressive effect of novel phosphodiesterase 4 (PDE4) inhibitor ONO-6126 on TNF-alpha release was increased after repeated oral administration in healthy Japanese subjects. Eur Respir J 2003, 22 (Suppl. 45): Abst 2557.
138. Aubier, M., Nagy, G.B., Sauer, R., Schmid-Wirlitsch, C., Albrecht, A., Bredenbroker, D. The novel selective PDE4 inhibitor roflumilast: Early onset of efficacy in asthma. Eur Respir J 2003, 22 (Suppl. 45): Abst 1392.
139. Bateman, D., Izquierdo, L., Vetter, N., Schmid-Wirlitsch, C., Bredenbroeker, D. Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma. Eur Respir J 2003, 22 (Suppl. 45): Abst 1393.
140. Klugman, K.P., Madhi, S.A., Huebner, R.E., Kohberger, R., Mbelle, N., Pierce, N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. New Engl J Med 2003, 349(14): 1341.
141. Knapp, A.G., Tally, F.P., Arbeit, R.D. Skeletal muscle effects in patients receiving once-daily daptomycin (DAP) for complicated skin and skin structure infection (cSSSI). 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14, 2003, Chicago) 2003: Abst L-736.
142. Campanaro, E.S., Tally, F.P., Eisenstein, B.I., Arbeit, R.D. Comparison of efficacy and safety of daptomycin (DAP) versus semi-synthetic penicillin (SSP) and vancomycin (VAN) in patients with complicated skin and skin structure infections (cSSSI). 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14. 2003, Chicago) 2003: Abst L-737.
143. Postier, R., Klein, S., Green, S., Loh, E. Results of a phase 2, open-label, safety, and efficacy study of tigecycline to treat complicated skin and skin structure infections in hospitalized patients. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14, 2003, Chicago) 2003: Abst L-738.
144. Viayna, C., Alvarez, D., Domper, N., Puerta, L., Martínez, D.,
145. Fechner, J., Ihmsen, H., Hatterscheid, D. et al. Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. Anesthesiology 2003, 99(2): 303.
146. Nasveld, P., Kitchener, S., Edstein, M., Rieckmann, K. Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria) in Australian Defence Force personnel. Trans R Soc Trop Med Hyg 2002, 96(6): 683.
147. Nasveld, P., Brennan, L., Edstein, M., Kitchener, S., Leggat, P., Rieckmann, K. A randomised, double-blind comparative study to evaluate the safety, tolerability and effectiveness of tafenoquine and mefloquine for the prophylaxis of malaria in non-immune Australian soldiers. 51st Annu Meet Am Soc Trop Med Hyg (Nov 10, 2002, Denver) 2002: Abst 326.
148. Peters, F., Cohen, A.T., Agnelli, G. et al. Ximelagatran, and its subcutaneous form melagatran, versus enoxaparin as thromboprophylaxis in total hip or total knee replacement. Br J Haematol 2003, 121 (Suppl. 1): Abst 125.
149. Amantea, M.A., Raber, S., Reynolds, R. et al. Dose-dependent effect of capravirine (CPV) on the pharmacokinetics (PK) of lopinavir/ritonavir (LPV/RTV) in healthy volunteers. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14, 2003, Chicago) 2003: Abst A-1608.
150. Chalon, S.A., Granier, L.-A., Vandenhende, F.R. et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: A double-blind, controlled study. Neuropsychopharmacology 2003, 28(9): 1685.
151. Nord, C.E., Meurling, L., Russo, R.L., Bello, A., Grasela, D.M., Gajjar, D.A. Effect of garenoxacin on eubacteria in the normal intestinal microflora when administered concomitantly with digoxin. J Chemother 2003, 15(3): 244.
152. Grillon, C., Cordova, J., Levine, L.R., Morgan, C.A. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology 2003, 168(4): 446.
153. Ullmann, U., Haller J., Decourt, J.P. et al. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res 2003, 31(2): 88.
154. Vella, A., Shah, P., Reed, A.S., Adkins, A.S., Basu, R., Rizza, R.A. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 2002, 45(10): 1410.
155. Fiorucci, S., Santucci, L., Wallace, J.L. et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA 2003, 100(19): 10937.
156. Greenblatt, D.J., Harmatz, J.S. Effect of age and gender on the pharmacodynamics of TAK-375: Tests of sedation, psychomotor function, and memory. Sleep 2003, 26 (Suppl.): Abst 0197.C.
157. Stubbs, C., Karim, A. A safety, tolerance, and pharmacokinetic study of five single doses of TAK-375 in healthy adults. Sleep 2003, 26 (Suppl.): Abst 0187.C.
158. Cattaneo, C., Caccia, C., Marzo, A., Maj, R., Fariello, R.G. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin Neuropharmacol 2003, 26(4): 213.
159. Amantea, M.A., Raber, S., Reynolds, R. et al. Pharmacokinetic (PK) drug-drug interaction between capravirine (CPV), lopinavir/ritonavir (LPV/RTV), and tenofovir (TDF) in healthy volunteers. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14, 2003, Chicago) 2003: Abst A-1609.